Mylan Sulfamylon Burn Efficacy Study Will Be Conducted In Phase IV

Mylan will perform an efficacy study of the burn treatment agent Sulfamylon (mafenide acetate for solution) as one of its Phase IV commitments after receiving accelerated approval June 5.